Automotive Digital Keys Strategic Business Report 2025: Global Market to Reach $8.6 Billion by 2030 - NFC, BLE, and UWB Technologies Compete in Enhancing Security and Usability of Digital Keys
Understand the significant growth trajectory of the Switches Component segment, which is expected to reach US$3.6 Billion by 2030 with a CAGR of a 21.8%. The Sensors Component segment is also set to grow at 15.7% CAGR over the analysis period. Gain insights into the U.S. market, valued at $812.7 Million in 2024, and China, forecasted to grow at an impressive 26.4% CAGR to reach $2.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Automotive Digital Keys Market
Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Automotive Digital Keys - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Automotive Digital Keys was valued at US$3.0 Billion in 2024 and is projected to reach US$8.6 Billion by 2030, growing at a CAGR of 19.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Automotive Digital Keys market.
Automotive digital keys are transforming traditional vehicle access by enabling secure, smartphone-based entry and ignition systems that align with the growing shift toward connected, contactless, and personalized mobility. Replacing or augmenting physical key fobs, these digital solutions allow authorized users to lock, unlock, and start vehicles using mobile apps, wearable devices, or biometric authentication methods. As vehicles become more software-defined and embedded with IoT connectivity, digital keys are evolving from convenience features into strategic enablers of shared mobility, fleet management, and customer-centric ownership experiences.What Is Fueling the Global Growth of the Automotive Digital Keys Market?The growth of the automotive digital keys market is underpinned by converging trends in connected mobility, cybersecurity innovation, and consumer demand for seamless digital experiences. As vehicles become more connected and autonomous, the need for secure, flexible, and scalable access control is escalating - driving widespread interest in digital key technologies across OEMs, suppliers, and mobility providers. The shift toward app-based vehicle ecosystems, integration with smart home devices, and real-time data analytics is positioning digital keys as gateways to broader vehicle interaction and service personalization.OEM strategies to future-proof their platforms through over-the-air (OTA) updates and modular software integration are also accelerating digital key rollouts, especially in software-defined vehicles that prioritize continuous enhancement. Regulations around digital identity, secure communication, and data privacy are fostering greater focus on cybersecurity compliance, prompting manufacturers to invest in hardened, standards-compliant digital key systems. As the automotive landscape shifts toward electrification, shared usage, and personalized digital ecosystems, a key question defines the future: Can automotive digital keys scale across platforms, users, and use cases to become the universal, secure access layer of next-generation mobility?How Are Standards, Security Protocols, and Integration Platforms Advancing Digital Key Capabilities?The evolution of automotive digital keys is being driven by robust security protocols, global standardization efforts, and the integration of mobile operating systems with vehicle control units. The Car Connectivity Consortium (CCC) has been instrumental in developing a standardized Digital Key specification - now in its 3.0 iteration - which uses ultra-wideband (UWB), Bluetooth Low Energy (BLE), and near-field communication (NFC) technologies to ensure secure, passive, and proximity-based access. These standards enable interoperability across OEMs, mobile devices, and Tier 1 suppliers, fostering scalability and user adoption across brands and platforms.End-to-end encryption, tokenization, and embedded secure elements within smartphones ensure that digital key data is tamper-proof, non-clonable, and revocable in real-time. Integration with mobile wallets (e.g., Apple Wallet, Samsung Pass) allows users to store digital keys alongside credit cards and boarding passes, simplifying user experience. Advanced solutions are incorporating biometric authentication, remote key sharing, geofencing, and time-restricted access - all managed through cloud-based platforms that synchronize with vehicle telematics systems. These developments are enabling a seamless, secure, and software-upgradable user experience, while reducing reliance on mechanical or proximity-based physical keys.Where Is Demand for Automotive Digital Keys Accelerating and Which Vehicle Segments Are Leading Deployment?Global demand for automotive digital keys is growing rapidly across both premium and mass-market vehicle segments, with the strongest traction in North America, Europe, China, and South Korea. OEMs in these regions - such as BMW, Hyundai, Tesla, and Mercedes-Benz - are leading deployment, offering digital key functionality as part of their connected vehicle suites. The luxury vehicle segment was the first to adopt digital keys, driven by a focus on premium user experience and technology leadership. However, mainstream automakers are quickly following suit, integrating digital key features in mid-segment EVs, crossovers, and SUVs to appeal to digitally native consumers.Electric vehicles (EVs) are particularly aligned with digital key adoption, as their centralized electronic architecture and app-based user interfaces support seamless feature integration. Shared mobility platforms, car rental agencies, and corporate fleet operators are also increasingly adopting digital keys to streamline vehicle handovers, reduce physical key logistics, and enhance asset utilization. Additionally, automotive start-ups and subscription-based mobility providers are embedding digital key platforms to enable user authentication, access tracking, and remote customer onboarding. The rise of vehicle-as-a-service (VaaS) models further cements digital keys as a foundational enabler of new ownership and access paradigms.Report Scope
Report Features:
Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of players such as ALPHA Corporation, BMW AG, Car Keys Express, Continental AG, DENSO Corporation and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Segments:
Component (Switches Component, Sensors Component, Electronic Control Units Component, Other Components)
Connectivity (Remote Cloud Key Access Connectivity, Biometric Connectivity, Near Field Communication Connectivity, Bluetooth Connectivity, Wi-Fi Connectivity)
Technology (Passive Keyless Entry System Technology, Remote Keyless Entry System Technology)
Application (Vehicle Engine Start / Stop Application, Fleet Management Application, Vehicle Security Application, Charging Application, Payment Application, Shared Mobility Application, Other Applications)
Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition:
Tariff-adjusted market forecasts by region and segment
Analysis of cost and supply chain implications by sourcing and trade exposure
Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
Finalized tariff impacts and new trade agreement effects
Updated projections reflecting global sourcing and cost shifts
Expanded country-specific coverage across the industry
Key Attributes:
Report Attribute
Details
No. of Pages
340
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$3 Billion
Forecasted Market Value (USD) by 2030
$8.6 Billion
Compound Annual Growth Rate
19.2%
Regions Covered
Global
Key Topics Covered: MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Automotive Digital Keys - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
MARKET TRENDS & DRIVERS
Smartphone-Based Digital Key Solutions Redefine Vehicle Access and Personalization Standards
Standardization Efforts by Car Connectivity Consortium Accelerate OEM Adoption of Digital Keys
NFC, BLE, and UWB Technologies Compete in Enhancing Security and Usability of Digital Keys
Sharing Functionality for Valets, Fleet, and Family Users Expands Use Case Versatility
Automotive App Ecosystems Evolve to Integrate Digital Key Management Features
Digital Key Technology Enhances Brand Loyalty by Elevating User Experience
Remote Vehicle Access and Control Features Boost the Appeal of Subscription-Based Digital Key Services
Multi-Factor Authentication Models Improve Theft Protection in Digital Key Systems
Integration With Smart Home and Digital Identity Platforms Expands Key Utility Beyond Vehicles
Premium Vehicle Segments Lead Adoption Curve With Embedded Digital Key Capabilities
Insurance Providers Explore Digital Key Data for Risk Scoring and Claims Verification
Keyless Entry Convenience Combines With Sustainability by Reducing Hardware Fob Production
FOCUS ON SELECT PLAYERS:Some of the 32 companies featured in this report
ALPHA Corporation
BMW AG
Car Keys Express
Continental AG
DENSO Corporation
Everykey Inc.
Ford Motor Company
General Motors Company
Geotab Inc.
Heights Security Inc.
HELLA GmbH & Co. KGaA
Hyundai Mobis Co., Ltd.
Hyundai Motor Company
Marquardt Group
Mitsubishi Electric Corporation
NXP Semiconductors N.V.
Robert Bosch GmbH
Samsung Electronics Co., Ltd.
STMicroelectronics N.V.
Tesla, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/g5hv9i
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Automotive Digital Keys Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
30 minutes ago
- Business Upturn
Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its Phase II study of the MDM2-p53 inhibitor alrizomadlin (APG-115) as a single agent or in combination with PD-1 inhibitor toripalimab in patients with advanced adenoid cystic carcinoma (ACC) or other solid tumors in a poster presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting. Alrizomadlin is the first MDM2-p53 inhibitor to enter clinical development in China and a key investigational drug candidate in Ascentage Pharma's apoptosis-targeted pipeline with global first-in-class potential. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. Returning to the ASCO Annual Meeting for the eighth consecutive year, Ascentage Pharma has garnered growing interest from the global research community. This year, two studies of the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin, key drug candidates in the company's apoptosis-targeted pipeline, have been selected for presentations, including an oral presentation, at the ASCO Annual Meeting. These clinical data on alrizomadlin in ACC and other solid tumors demonstrated the antitumor activity of alrizomadlin monotherapy in patients with advanced ACC or malignant peripheral nerve sheath tumor (MPNST). Moreover, alrizomadlin in combination with toripalimab was well tolerated and showed therapeutic potential in MPNST, biliary-tract cancer (BTC), and liposarcoma (LPS). Prof. Ye Guo, MD, a Principal Investigator of the study from the Department of Medical Oncology, Shanghai East Hospital, noted, 'ACC is a rare cancer type that lacks effective treatment options, and the treatment with antiangiogenic tyrosine kinase inhibitors faces certain limitations and safety concerns. At ASCO 2025, our team presented data of alrizomadlin in patients with ACC that demonstrated an objective response rate (ORR) of 16.7% and a disease control rate (DCR) of 100%. These results suggest that the targeted inhibition of the MDM2-p53 pathway has antitumor activity in ACC; therefore, it can potentially offer a new treatment strategy to patients with ACC.' Prof. Ning Li, MD, a Principal Investigator of the study from the Chinese Academy of Medical Sciences Cancer Hospital, commented, 'Currently, there are limited treatment options for patients with sarcomas such as MPNST and LPS. In this study, alrizomadlin both as a monotherapy and in combination with a PD-1 therapy, showed favorable antitumor activity in MPNST. The clinical benefit was particularly notable in patients who received the combination regimen, with two patients with MPNST achieving long-term responses that lasted more than 60 and 96 weeks, respectively. Furthermore, alrizomadlin in combination with a PD-1 therapy also showed clinical activity in LPS. These results suggest that alrizomadlin monotherapy and combination regimens may bring clinical benefit to more patients with sarcoma.' Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Alrizomadlin is an investigational drug with global first-in-class potential. The clinical data presented at this year's ASCO Annual Meeting demonstrated the therapeutic potential of alrizomadlin, both as a monotherapy and in combinations, in ACC and other solid tumors, and underscored the synergistic effects between alrizomadlin and immunotherapies, thus suggesting a promising therapeutic strategy for various solid tumors. We are focused on addressing unmet clinical needs in China and around the world, and intend to further accelerate our clinical programs to advance more novel treatment options for patients as soon as possible.' Highlights of this abstract selected for presentation at ASCO 2025 are as follows: A Phase 2 Study of Novel MDM2 Inhibitor Alrizomadlin (APG-115) With or Without Toripalimab in Patients with Advanced Adenoid Cystic Carcinoma (ACC) or Other Solid Tumors Abstract #: 6102 6102 Format: Poster Presentation Poster Presentation Session Title: Head and Neck Cancer Head and Neck Cancer Principal Authors: Ye Guo, MD, Department of Medical Oncology, Shanghai East Hospital, China; Ning Li, MD, Chinese Academy of Medical Sciences Cancer Hospital, China; Xing Zhang, MD, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, China; Meiyu Fang, MD, Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, China; Shuhang Wang, MD, Chinese Academy of Medical Sciences Cancer Hospital, China, et al. Ye Guo, MD, Department of Medical Oncology, Shanghai East Hospital, China; Ning Li, MD, Chinese Academy of Medical Sciences Cancer Hospital, China; Xing Zhang, MD, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, China; Meiyu Fang, MD, Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, China; Shuhang Wang, MD, Chinese Academy of Medical Sciences Cancer Hospital, China, et al. Highlights: Alrizomadlin is a novel investigational oral MDM2 inhibitor that has shown a manageable safety profile with initial clinical activity in ACC. As of the data cutoff date of February 13, 2025, 57 patients with advanced ACC, malignant peripheral nerve sheath tumor (MPNST), liposarcoma (LPS), biliary-tract cancer (BTC), and other tumors were enrolled. Alrizomadlin monotherapy showed encouraging antitumor activity in patients with advanced ACC or MPNST. Alrizomadlin in combination with toripalimab was also well tolerated and demonstrated antitumor activity in patients with MPNST, BTC, and LPS. In the monotherapy arm, 17 patients were efficacy-evaluable. The ORR was 16.7%, and the DCR was 100% in 12 patients with ACC. The DCR was 80% in 5 patients with MPNST, 4 of whom achieved stable disease (SD). In 24 safety-evaluable patients, 33.3% reported grade 3 or higher treatment-related adverse events (TRAEs). Three patients (12.5%) experienced treatment-related serious adverse events (SAEs). One patient discontinued treatment because of TRAE. In the combination arm, 29 patients were efficacy-evaluable. The ORR was 16.7% and the DCR was 100% in 6 patients with BTC. The ORR was also 16.7% and the DCR was 66.7% in 6 patients with LPS. Two patients with MPNST had confirmed partial response (PR) with prolonged progression free survival (PFS) of 60 + weeks and 96 + weeks, respectively. In 27 safety-evaluable patients treated with alrizomadlin at the 150 mg dose level, 12 (44.4%) experienced grade 3 or higher TRAEs. Treatment-related SAEs were reported in 8 patients (29.6%). One patient discontinued treatment because of TRAE. * Alrizomadlin (APG-115) is an investigational compound and has not been approved by the US FDA. About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph+ ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematological malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with sub-optimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations:Hogan Wan, Head of IR and StrategyAscentage Pharma [email protected] +86 512 85557777
Business Upturn
30 minutes ago
- Business Upturn
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. ('Nxera' or 'the Company'; TSE 4565) today announces that its partner, Neurocrine Biosciences ('Neurocrine') has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-'568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: NCT06963034). The US$15 million payment will be fully recognized as revenue in the second quarter of 2025. Nxera previously announced the initiation of the Phase 3 registrational program of NBI-'568 by Neurocrine in May 2025. The Phase 3 study is a global double-blind, placebo-controlled trial evaluating NBI-'568 in adults with a primary diagnosis of schizophrenia who are experiencing an acute exacerbation or relapse of symptoms. The study is expected to enroll approximately 280 patients. The primary endpoint of the study is a reduction from baseline in the Positive and Negative Syndrome Scale (PANSS). The key secondary endpoint is improvement in the Clinical Global Impression of Severity (CGI-S) scale. –END– About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology/neuropsychiatry, metabolic diseases and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager +81 (0)3 5962 5718 | +44 (0)1223 949390 |[email protected]
Business Upturn
30 minutes ago
- Business Upturn
Canadian Health Tech Cuts Hospital Emergency Department Triage Time by up to 60%
Photo Courtesy of EmergConnect TORONTO, June 02, 2025 (GLOBE NEWSWIRE) — EmergConnect's digital platform helps hospitals cut ER triage time by up to 60%. The system gives patients real-time wait estimates, supports nursing staff, and is gaining traction as an early solution for Canada's strained emergency departments. 'We've seen ER triage times cut by up to 60% with our platform,' says Ron Galaev, founder and CEO of EmergConnect. 'It's about giving nurses back their time and giving patients the clarity they deserve—because uncertainty shouldn't be part of seeking care.' Hospitals using EmergConnect allow patients to begin their emergency department visit before they even walk through the door, or comfortably in their seat in the waiting room. Individuals can enter symptoms and details through their phones, register in advance, and receive an estimate of how long they might wait. Nurses then review the information in the EmergConnect portal and send it straight into their hospitals' system with just one click. The company worked for eight months with national and provincial health groups to create a tool compatible with current triage standards. The platform also includes tools for paramedics, to reduce offload times, and a redirection system that directs patients to less crowded hospitals nearby or for lower acuity patients alternative care options altogether. 'When we first started analyzing emergency departments, we were shocked to discover nurses had to click 64 times just to intake a single patient, we've reduced that to just four clicks' says Marina Gavrilov, CTO of EmergConnect. Hospitals say the platform reduces staff pressure by cutting out manual steps from the intake process. Hospitals use EmergConnect's tools to direct patients who do not need emergency care to nearby clinics, easing demand. Its AI-based predictions give individualized wait times, tailored to the hospital's current situation. 'By eliminating manual steps and guiding non-urgent cases to nearby clinics, we're helping hospitals ease pressure on staff while ensuring patients get the right care, faster,' Galaev explains. 'Our AI doesn't just estimate wait times,it personalizes them based on what's actually happening inside the hospital.' The company raised $2 million CAD in late 2024 and plans to expand to British Columbia and Quebec. It also considers tackling problems facing the U.S. system next. 'We help hospitals solve one of the biggest day-to-day problems they face,' Galaev said. EmergConnect's leaders believe the tool will serve more hospitals seeking to improve efficiency and patient experience. Four large hospital systems already use the product, and the company says interest is growing quickly, with aims at having the majority of the Canadian healthcare system covered in the coming years. As emergency departments continue to face staffing shortages and surging demand, tools like EmergConnect are becoming part of more conversations between hospital administrators and frontline staff. About EmergConnect EmergConnect is a Canadian digital health company focused on improving same-day care through an integrated triage and registration platform. Designed for patients, nurses, paramedics, and administrators, the system helps reduce emergency room wait times, streamline intake, and improve care navigation. EmergConnect partners with hospitals across Ontario and is expanding nationally. Contact Information: Contact Person's Name: Maya MeyouhasOrganization / Company: EmergConnectCompany website: Contact Email Address: [email protected] City, State / Province, Country: Toronto, Ontario, Canada
